Media Coverage

Pre-existing Immunogenicity: How Will Cell and Gene Therapies Change Our Testing Approach?

In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave of C&GTs entering the development pipeline and the considerations they must make in their pre-existing immunogenicity assessments.

Click for full article

molecule 3d rendering